(Q38180747)

30 August 2017

Use of infliximab and other biologics in Behçet disease (English)

1 reference

30 August 2017

0 references

J Li

1

1 reference

30 August 2017

S Fernando

series ordinal

2

1 reference

30 August 2017

G Herkes

series ordinal

3

1 reference

30 August 2017

language of work or name

1 reference

1 January 2014

1 reference

Internal Medicine Journal

30 August 2017

1 reference

30 August 2017

44

1 reference

30 August 2017

1

1 reference

30 August 2017

96-100

1 reference

Neuro-Behçet's disease: epidemiology, clinical characteristics, and management

30 August 2017

1 reference

Behçet's disease--a contemporary review

21 January 2018

1 reference

Clinical patterns of neurological involvement in Behçet's disease: evaluation of 200 patients. The Neuro-Behçet Study Group

21 January 2018

1 reference

Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behçet disease

21 January 2018

1 reference

Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial

21 January 2018

1 reference

Effect of infliximab in progressive neuro-Behçet's syndrome

21 January 2018

1 reference

Infliximab for the treatment of Neuro-Behçet's disease: a case series and review of the literature

21 January 2018

1 reference

Successful use of infliximab in a patient with neuro-Behçet's disease.

21 January 2018

1 reference

Infliximab for patients with neuro-Behcet's disease: case series and literature review.

21 January 2018

1 reference

Anti-tumor necrotic factor antibody for treatment of neuro-Behçet's disease, a case report.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/IMJ.12297

1 reference

30 August 2017

1 reference